Safety Profile and Effects of Pulsed Methylprednisolone on Vital Signs in Thyroid Eye Disease

Table 1

Characteristics of study population.

	Overall ( = 38)
Mean age (SD), years	48.81 ± 8.8
Male (ratio)	25 (65.8%)
Mean number of cycles (SD)	2.34 ± 1.53
Range	1–7
Smoking status
Current smokers	10 (26.3%)
Nonsmokers	24 (63.2%)
Ex-smokers	4 (10.5%)
Preexisting comorbidities
Heart disease	3 (7.9%)
Hyperlipidemia	4 (10.5%)
Stroke	1 (3.2%)
Diabetes	7 (18.4%)
Preexisting hepatitis (hepatitis B carrier)	3 (9.1%)
Indication for IVMP
Active TED	26 (68.4%)
Compressive optic neuropathy	12 (31.6%)
Adjuvant therapy and subsequent surgery
Methotrexate	26 (68.4%)
Radiotherapy	10 (26.3%)
Decompression surgery	8 (21.1%)
Mean duration of hyperthyroidism (SD), years	3.56 ± 5.76
Thyroid status
Euthyroid	9 (23.7%)
Hyperthyroid	22 (57.9%)
Hypothyroid	6 (15.8%)

SD: standard deviation; IVMP: intravenous methylprednisolone; TED: thyroid eye disease.